Dr. Joyce Varughese, MD

Dr. Varughese practices at Capital Health Medical Center - Hopewell in Pennington, New Jersey, part of Capital Health System.

Dr. Varughese's NPI, 1326222589, was assigned on December 24, 2007. Dr. Varughese graduated from Albert Einstein College of Medicine of Yeshiva University in 2006. Dr. Varughese holds New Jersey license 25MA09979600.

Dr. Varughese's primary practice is Capital Health Medical Center - Hopewell, at One Capital Way, Pennington, NJ 08534 in Mercer County. The practice phone is (609) 303-4000. Dr. Varughese also practices at Capital Health Medical Center - Hopewell, 1 Capital Way, Pennington, NJ 08534.

Dr. Varughese's primary practice is Capital Health Medical Center - Hopewell in Pennington, New Jersey, part of Capital Health System. The medical group on file is Capital Health Medical Group. Dmand AI also links Dr. Varughese to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Varughese practices, 3 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Varughese's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dmand AI has Dr. Varughese's licenses on file in 3 states: New Jersey, New York and Pennsylvania.

CMS data shows 326 Medicare services from Dr. Varughese across 6 procedure codes in 2024, for 116 Medicare patients. Medicare paid $30,400 for them.

CMS counts 116 Medicare patients who saw Dr. Varughese in 2024. The largest group is 65 to 74, with 50 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 19% are also on Medicaid. Their average risk score is 1.54, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Varughese's median patient age at 64, with 98% women.

In 2024, Dr. Varughese wrote 71 Medicare Part D claims for 48 patients. 94% of them were for generic drugs. CMS names the drug for 23 of them, across 1 drug with 11 or more claims each, at $19 in total drug cost. In 2023, CMS named 38 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Dr. Varughese for performance year 2024, reported through an alternative payment model (APM). Dr. Varughese accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Varughese as offering telehealth.

Colonoscopy: 1 to 10 procedures (CMS shows small counts as a range)

Removal of the uterus: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 26 papers to Dr. Varughese, published from 2011 to 2024. 2011 was the busiest year, with 11. The most frequent topics are Cell Line, Tumor, Uterine Neoplasms and Antibodies, Monoclonal. Dr. Varughese has published most often in Gynecol Oncol. Dr. Varughese's most frequent co-authors are Alessandro D. Santin, MD, Masoud Azodi, MD and Elena S. Ratner, MD.

Dmand AI links Dr. Varughese to 3 clinical trials. 2 are still active or recruiting. Conditions studied include Brenner Tumor, Endometrial Hyperplasia and Fallopian Tube Diseases.

CMS Open Payments shows 24 general payments to Dr. Varughese from 13 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 57% of the total. Ethicon Inc. paid the most, $10,182.

Dr. Varughese graduated from Albert Einstein College of Medicine of Yeshiva University in 2006.